Aligos Therapeutics, Inc.
ALGS
$6.48
-$1.10-14.51%
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
--
Headlines
4/1/2025
-
MarketBeat
3/27/2025
-
TipRanks Financial Blog
3/27/2025
-
The Fly
3/26/2025
-
GuruFocus
3/26/2025
-
The Fly
3/26/2025
-
Globe Newswire
3/14/2025
-
GuruFocus
3/14/2025
-
The Fly
3/14/2025
-
Globe Newswire
3/12/2025
-
TipRanks Financial Blog
3/11/2025
-
The Fly
3/11/2025
-
TipRanks Financial Blog
3/10/2025
-
Zacks Investment Research
3/10/2025
-
GuruFocus
3/10/2025
-
The Fly
3/10/2025
-
SeekingAlpha.com: All News
3/10/2025
-
Globe Newswire
3/7/2025
-
ETF Channel
3/5/2025
-
MarketBeat
3/4/2025
-
MarketBeat
3/3/2025
-
GuruFocus
3/3/2025
-
Globe Newswire
2/17/2025
-
MarketBeat
2/15/2025
-
GuruFocus
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Monday, March 10, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
800-466-6059
Address
One Corporate Drive
South San Francisco, CA 94080
South San Francisco, CA 94080
Country
Year Founded
Business Description
Sector
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug...
more
